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Cell-free heme (CFH) and hemoglobin (Hb) have emerged as distinct mediators of acute injury char-
acterized by inﬂammation and microcirculatory dysfunction in hemolytic conditions and critical illness.
Several reports have shown changes in Hb and CFH in speciﬁc pathophysiological settings. Using PBS,
plasma from patients with sickle cell disease, acute respiratory distress syndrome (ARDS) patients and
supernatants from red cells units, we found that commonly used assays and commercially available kits
do not distinguish between CFH and Hb. Furthermore, they suffer from a variety of false-positive in-
terferences and limitations (including from bilirubin) that lead to either over- or underestimation of CFH
and/or Hb. Moreover, commonly used protocols to separate CFH and Hb based on molecular weight
(MWt) are inefﬁcient due to CFH hydrophobicity. In this study, we developed and validated a new ap-
proach based on absorbance spectrum deconvolution with least square ﬁtting analyses that overcomes
these limitations and simultaneously measures CFH and Hb in simple aqueous buffers, plasma or when
associated with red cell derived microvesicles. We show how incorporating other plasma factors that
absorb light over the visible wavelength range (speciﬁcally bilirubin), coupled with truncating the wa-
velength range analyzed, or addition of mild detergent signiﬁcantly improves ﬁts allowing measurement
of oxyHb, CFH and metHb with 490% accuracy. When this approach was applied to samples from SCD
patients, we observed that CFH levels are higher than previously reported and of similar magnitude to
Hb.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Cell free heme (plasma free hemeþplasma protein bound
heme) (CFH) and cell free hemoglobin (Hb), are mediators of tissue
injury in hemolytic diseases (e.g. sickle cell disease (SCD), trans-
fusion toxicity, cardiopulmonary bypass, dialysis, infection [1–14])B.V. This is an open access article u
niversity of Alabama at Bir-
irmingham, AL 35294, United
l).as well as other diseases not typically associated with hemolysis
including environmental poisons and sepsis [15–21]. Cell-free Hb
is a potent scavenger of nitric oxide (NO), activates inﬂammation
and undergoes redox cycling reactions that cause oxidative stress
[1,8,22–25]. Cell-free heme also stimulates oxidative stress, acti-
vates TLR4, and the inﬂammasome leading to exacerbated in-
ﬂammation-mediated tissue injury [7,9,19,26–29]. Thus, CFH and
Hb elicit tissue injury by overlapping and distinct mechanisms.
Because of the implication that CFH and Hb levels may have on
disease mechanisms and therapeutics, it is imperative that meth-
ods used to measure each are accurate, sensitive and reproducible.
In vivo, CFH and Hb will co-exist and need to be distinguishednder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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used to measure CFH and Hb in biological matrices. However,
these typically rely on a colorimetric detection of CFH and Hb
under conditions that may cause Hb denaturation and heme re-
lease. Therefore they are unlikely to distinguish between CFH and
Hb. Other approaches that improve sensitivity utilize the pseudo-
peroxidase activity of heme, and link heme to a reporter molecule
whose oxidation can be detected by a change in absorbance or
ﬂuorescence. Again, these approaches would not distinguish be-
tween CFH and Hb, as both are redox active. Our assessment of the
literature is that these considerations are often overlooked when
measuring CFH and Hb. When appreciated, separation methods
based on differing size of CFH and Hb are employed (e.g. Centricon
ﬁltration devices). However, these are typically not optimized for
separation of hydrophobic compounds such as CFH.
To our knowledge, no systematic study comparing different
CFH and Hb measurement protocols have been reported. In this
study, we demonstrate that commonly used methods to measure
CFH and Hb do not distinguish between them, presenting a pro-
blem when both are present in the same medium. We develop a
method based on spectral deconvolution, allowing for simulta-
neous and rapid measurement of CFH and Hb in simple aqueous
systems and plasma. Pros and cons are discussed and applicability
to evaluate CFH and Hb in clinical samples demonstrated.2. Materials and methods
2.1. Materials
All chemicals, reagents and assay kits were purchased from
Sigma unless otherwise noted.
2.2. Plasma preparation
Blood was collected by venipuncture from healthy volunteers
per UAB IRB approved protocols, and centrifuged 1500 g, 4 °C,
10 min to pellet red blood cells (RBCs). Plasma was collected,
stored on ice and used within 24 h.
2.3. Trauma-hemorrhage patient's sample collection
Blood was collected from 37 resuscitated trauma patients ac-
cording to UAB IRB approved protocols. Blood was centrifuged
within 60 min of collection and plasma stored at 4 °C for up to
72 h before freezing in liquid nitrogen. Samples were stored at
80 °C and subsequently thawed on ice for spectral
measurements.
2.4. Critically ill patients' sample collection
Plasma was collected from patients with ARDS secondary to
Gram negative sepsis and from other critical non-pulmonary
conditions, who were intubated and mechanically ventilated in
the medical intensive care unit at UAB. All human studies were
approved by the UAB Institutional Review Board.
2.5. Sickle cell disease (SCD) patient's sample collection
Within 24 h of admission, blood was collected from SCD pa-
tients per UAB IRB approved protocols and recollected every 24 h
until discharge or until logistical constraints prevented collection.
In order to be included, patients had to have homozygous Hb SS or
Hb S Beta Thalassemia (Hb SB0), be 1–21 years old, and admitted
for acute chest syndrome (ACS) or vaso-occlusive pain crisis (VOC).
Control samples were collected from age-matched AfricanAmerican patients without SCD. Blood was collected in sodium
citrate tubes, immediately placed on ice and centrifuged at
1500 rpm, 4 °C for 15 min, within 30 min of collection. Plasma was
aliquoted and stored at 4 °C until the aliquots could be rapidly
frozen using liquid nitrogen.
2.6. Stored RBC sampling and microvesicle preparation
Leukoreduced RBCs (from six distinct blood donors, with 2 bags
collected from one donor) in Adsol were sampled from bags stored
for 30–52d in the UAB Blood Bank. Bags were allocated for disposal
or expired. RBC were centrifuged 3000 g, 10 min, 4 °C to pellet
RBC and provide supernatants. The latter were further processed
to isolate microparticles (MP) and exosomes (Exo) by two cen-
trifugations at 10,000 g, 30 min, 4 °C (spin 2 and 3) followed by a
150,000 g, 2 h, 4 °C (spin 4) centrifugation. Pellets from spins
2 and 3 were combined to give MPs, and pellet from spin 4 con-
tained exosomes. Microvesicle size and number were determined
using an NS300 Nanosight (Malvern, UK) with an attached syringe
sample pump and 405 nm laser.
2.7. Hemoglobin preparation
Cell-free oxyHb was puriﬁed from RBCs and catalase removed
as described [30,31]. All hemoglobin was stored in the carbon-
monoxide ligated form, and converted to oxyHb or metHb
immediately prior to use as described [32]. For cyanide treatment,
potassium cyanide (500 mM in 0.1 M KOH) was added to Hb or
CFH resulting in cyanide: heme ratios 410; and pH was mon-
itored to keep at 7.4. Final concentration of cyanide is indicated in
text.
2.8. Cell-free heme (CFH) preparation
10 mM hemin (Frontier Scientiﬁc, UT) was prepared in 0.1 M
NaOH, then diluted to 100 μM in PBS, pH 7.4 at 22 °C, fresh on the
day of each experiment.
2.9. Conjugated and unconjugated bilirubin
Conjugated (Di-taurine conjugated) bilirubin and unconjugated
bilirubin (Lee BioSolutions, MO) were prepared in PBS (2 mg/mL)
and ethanol (1 mg/mL) respectively and diluted to indicated
concentrations.
2.10. Quantifying CFH, OxyHb, MetHb, and CN-Hb
All CFH and Hb levels are reported in heme (i.e. 1 μM Hb
tetramer will be 4 μM Heme expressed per Hb). Various protocols
were used to quantify CFH and Hb including:
i) QuantiChrom™ Heme Assay Kit and QuantiChrom™
Hemoglobin Assay Kit (BioAssay, Hayward, CA). CFH and Hb
levels were determined using manufacturer's protocols and
calibration standards provided. Changes in absorbance at
405 nm were measured using a 96-well plate reader (Victor3,
Perkin Elmer, MA).
ii) CFH or Hb were measured using the TMB Substrate Reagent
Set (BD Biosciences, San Jose, CA) with modiﬁcations to the
manufacturer's protocol: 50 mL PBS or 50 mL diluted plasma
(10–200x in PBS) were spiked with oxyHb or CFH to ﬁnal
concentrations of 0–2 mM. PBS or diluted plasma were then
mixed with 150 mL of a solution containing hydrogen peroxide
and TMB (prepared per manufacturer's instructions), all pre-
equilibrated at 37 °C prior to mixing. TMB-oxidation was
monitored continuously by following absorbance change at
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over 10 min at 37 °C. Initial rates were acquired and standard
curves constructed accordingly.
iii) Modiﬁed Drabkins assay: OxyHb was oxidized to metHb using
potassium ferricyanide (400 μM ﬁnal, 10 min at 22 °C), and
then to cyanometHb by adding potassium cyanide (500 μM
ﬁnal, 10 min at 22 °C). Change in absorbance at 540 nm pre-
and post- potassium cyanide was measured to determine Hb
concentration.
iv) ELISA: Hemoglobin levels were determined by sandwich ELISA
(Abcam, ab157707, MA) according to the manufacturer's in-
structions. Hb levels measured by ELISA were converted and
expressed as heme equivalents.Fig. 1. Cell-free heme (CFH) or hemoglobin (Hb) were dissolved at the indicated concent
kit for CFH (hemin kit) and Hb (Hb kit), and signal measured and quantiﬁed using manufa
PBS; Panel C plasma spiked with CFH and Panel D plasma spiked with oxyHb. Data are m
and show values after background subtraction. Best-ﬁt lines were determined by linea
measured concentrations from mixtures of CFH and oxyHb in PBS or plasma respectively
G: Plasma was collected from pediatric SCD patients or ARDS patients and CFH and Hb me
Each symbol represents a distinct patient sample. Only data with clinical measures of bil
regression (y¼6.8x1.6, po0.05 for deviation from zero).2.11. Cell-free heme (CFH) and hemoglobin (Hb) separation
Two approaches were tested. A) Centricon using Amicons Ultra
Centrifugal Filters (Merck Millipore Ltd, MA), with a 3 kDa MWt
cut-off: 100 mL of PBS or plasma containing CFH alone, Hb alone or
a mixture of both were added to Centricons and centrifuged at
14,000 g, 4 °C, 2 h. B) Desalting via Micro Bio-Spin™ size-ex-
clusion columns (Bio-Rad, CA), 6 kDa exclusion limit. 100 mL of PBS
or plasma with oxyHb and CFH were added to columns and cen-
trifuged at 1500 g, 22 °C for 2 min. Total heme level was de-
termined on pre- and post- Centricon or pre- and post- size-ex-
clusion columns to calculate the CFH by QuantiChrom™ Heme
assay kit.rations in either PBS or plasma and then measured using the QuantiChrom™ Assay
cturer provided standards. Panel A shows CFH alone in PBS, Panel B oxyHb alone in
ean7SEM, (n¼3, each replicate from a distinct PBS or plasma (donor) preparation
r regression. Indicated p-values show differences between lines. Panel E–F show
. Dashed line indicates expected values if kits were speciﬁc for CFH or oxyHb. Panel
asured using the QuantiChrom™ assay and plotted against the total bilirubin levels.
irubin were performed as standard of care are shown. Data were analyzed by linear
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Albumin was removed from plasma using the Pierce™ Albumin
Depletion Kit (Thermo Scientiﬁc, NY) according to the manufac-
turer's instructions and conﬁrmed by SDS-PAGE stained with
Coomassie Brilliant blue R-250 followed by densitometry.2.13. Plasma haptoglobin and hemopexin
Plasma haptoglobin and hemopexin were determined by ELISA
sandwich assay (Abcam, ab108858 and ab171576 respectively, MA)
according to the manufacturer's instructions.2.14. Spectral deconvolution
Standards for oxyHb, metHb, CFH, conjugated and un-
conjugated bilirubin and their respective cyano-derivatives were
prepared in PBS at pH 7.4 and absorbance between 450 and
700 nm measured by a Beckman UV-visible Spectrophotometer at
1 nm intervals, using 1 cm or 1 mm path length cuvettes at room
temperature. Spectra were analyzed by deconvolution algorithms
with multilinear regression ﬁtting (Excel) as described [6,33,34].2.15. Statistical analysis
All results are reported as the mean7SEM with signiﬁcant
differences considered as those with po0.05 using tests described
in ﬁgure legends and calculated using GraphPad Prism 5.Fig. 2. Cell-free heme (CFH) or hemoglobin (Hb) was dissolved at the indicated concentr
measured. For Panel B, representative data for 1 plasma preparation are shown after
sensitive than Hb, but in 100X diluted plasma, Hb was more sensitive. Panel C: Standard c
from 3 distinct donors. Data shows the slope for standard curves and are mean7SEM, (
differences between lines. *po0.01 by 2-way ANOVA with repeated measures. Panel D:
standard curve in transfused Trauma patient plasma where the ratio of Hb (in dimer; 1 H
groups by t-test.3. Results
3.1. Comparison of CFH and Hb assay kits
3.1.1. Sample alkalinization
CFH or oxyHb alone, or in combination (0–50 mM) were pre-
pared in PBS or plasma and then measured by the QuantiChrom™
Heme or Hemoglobin Assay Kits; both utilize changes in heme
absorbance at 405 nm, at alkaline pH. Fig. 1A–D shows that both
kits detect CFH and oxyHb, with no differences in the sensitivity
for either CFH or oxyHb, except for a very modest, but signiﬁcant
difference with oxyHb in PBS. Furthermore, when mixtures of CFH
and oxyHb were tested, each kit measured the sum of the added
components (Fig. 1E–F). A further limitation using this approach is
that sample displaying signiﬁcant absorbance in the visible range
will lead to false positives. In plasma, this is likely the case where
bilirubin is present [35]. Indeed, di-taurine conjugated or un-
conjugated bilirubin alone gave false positive signals in the
QuantiChrom™ Heme and Hemoglobin assay (not shown). Further
supporting this is positive correlation between total bilirubin le-
vels and CFHþHb signal in SCD and ARDS patient plasma (Fig. 1G).
3.1.2. Redox cycling
Another commonly used method utilizes H2O2-dependent
heme-redox cycling. Fig. 2 shows that the TMB assay measures
both CFH and Hb in a dose-dependent manner, but with different
sensitivities. For these measurements, TMB oxidation was followed
continuously at 600 nm to avoid false positive signals from bilir-
ubin. Fig. 2A shows that in PBS, Hb is more sensitive than CFH
whereas in plasma, the relative sensitivity was dependent on the
dilution employed (Fig. 2B). Fig. 2C shows the overall slope for
TMB oxidation (i.e. Hbþhemin) has little dependence on dilution
between 5 and 100 times. In other words, the TMB-dependent
signal for plasma does not change, but the relative contribution toations in either PBS (Panel A) or plasma (Panel B–C) and TMB oxidation at 600 nm
two different dilutions into the TMB assay. For 5X diluted plasma, CFH was more
urves for Hb and CFH (0–2 mM) dependent TMB oxidation were measured in plasma
n¼3). Best-ﬁt lines were determined by linear regression. Indicated P-values show
the sensitivity of the TMB assay was measured by determining the slope of the Hb
p binds 1 Hb dimer) remained either 41 or o1 relative to Hp. *po0.05 between
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tion. Plasma donor to donor variability was also noted in this assay
(not shown). We speculate this reﬂects the complex mixture of
compounds in plasma (e.g. ascorbate, urate, α-tocopherol, per-
oxides, hemopexin, haptoglobin) that may increase and/or de-
crease redox cycling kinetics. To illustrate this, we measured TMB
oxidation in plasma collected from resuscitated Trauma patients
which was spiked with different amounts of oxyHb to produce
samples where the concentration of Hb (in dimer) remained either
above or below the haptoglobin (Hp) concentration. When 41
(excess Hb), TMB oxidation was ∼two-fold higher (Fig. 2d), in-
dicating that a variable in the TMB assay is not only the amount of
Hb, but the relative ratio of Hp to Hb. A further consideration is
that inhibitory effect of haptoglobin on Hb redox cycling will de-
pend on the haptoglobin genotype [1].
3.2. Cell-free heme (CFH) and hemoglobin separation
Previous studies have separated CFH and Hb ﬁrst to delineate
the role of protein free vs. protein bound heme [7]. To test this,
solutions of CFH in PBS or plasma were ﬁltered through 3 kDa cut-
off Centricons (Fig. 3A). Fig. 3B–C shows that CFH levels decreasedFig. 3. Panel A: Scheme showing basis of CFH and Hb separation based on MWt ﬁltration
and post- centricon (3 kDa cut-off) by QuantiChrom™ Heme assay kit. Pre-Centricon conc
the blue line represents measurements of the post-Centricon ﬁltrate, and the dotted
measured and expected concentrations pre- and post- centricon separation of mixtures o
levels in plasma Panel E: Plasma was collected from pediatric SCD patients and total hem
3 kDa cut-off Centricon ﬁlters (red bars). Panel F: Scheme showing basis of CFH and Hb
combination were dissolved in PBS or plasma and passed through a size-exclusion col
Chrom™ Heme kit. Panel H: Hb and CFH were dissolved in PBS containing 500 mM album
shown are meanþSEM (n¼3). *po0.05 by paired t-test relative to pre-desalting. ND¼n
reader is referred to the web version of this article).after ﬁltration. Visual observation indicated brown coloration on
the membrane suggesting CFH adsorption likely due to hydro-
phobicity of CFH (not shown). This is further reﬂected when
mixtures of CFH and Hb were processed; Fig. 3D shows that CFH
was undetectable in the ﬁltrate, which would lead to CFH under-
estimation and Hb overestimation. Furthermore, Fig. 3E show total
heme levels in SCD plasma after MWt fractionation using 3 kDa
Centricons; consistent with Fig. 3A–D, ﬁltration decreased total
heme levels to ∼1 mM in all cases underscoring that this approach
does not separate CFH from Hb.
Next, we tested if a size-exclusion column would allow for
sufﬁcient separation of CFH from Hb (Fig. 3F). Fig. 3G shows that
with PBS, size-exclusion effectively removes CFH. However, in
plasma this was not observed (Fig. 3H). Measured concentrations
were the same before and after size-exclusion. This is likely due to
hydrophobic interactions between CFH and high MWt proteins
indicated by albumin [36] preventing separation of CFH from Hb in
PBS (Fig. 3H). However, CFH added into albumin depleted plasma
was still not separated by size-exclusion (Fig. 3H) suggesting that
multiple proteins might bind CFH and prevent its separation based
on MWt.. CFH (0–50 mM) dissolved in PBS (Panel B) or plasma (Panel C) was measured pre-
entrations of hemin in PBS (B) and plasma (C) are represented by the red line, while
black line represents the measurements expected post-Centricon. Panel D show
f CFH and oxyHb in PBS and plasma. Pre-centricon levels reﬂect baseline total heme
e measured using the QuantiChrom™ assay before and after sample ﬁltration using
separation using a size-exclusion column. Panel G: CFH alone, oxyHb alone, or the
umn and pre- and post-column levels of Hb and CFH measured using the Quanti-
in or albumin depleted human plasma, and processed as described in Panel G. Data
ot detectable. (For interpretation of the references to color in this ﬁgure legend, the
J.-Y. Oh et al. / Redox Biology 9 (2016) 167–1771723.3. Sample processing
Since sample collection and processing can affect Hb stability
which in turn will change the distribution between Hb and CFH,
without changing total levels, we tested various collection/storage
protocols. Plasma from healthy donors with low bilirubin was used
and recovery of added oxyHb or CFH determined. To selectively
measure Hb, the Drabkins assay was adapted to account for basal
plasma absorbance. Fig. 4A shows representative spectra of oxyHb,
metHb and cyanometHb in plasma. The absorbance change at
540 nm, between cyanometHb and metHb was used to determine
Hb concentration; delta extinction coefﬁcient calculated to be 4.3
mM1  cm1 and conﬁrmed in PBS (Fig. 4B). Fig. 4C shows that
ferricyanide/cyanide had no effect on CFH absorbance indicating
selectivity for Hb. Fig. 4D–E show that both Hb and CFH are fully
recoverable in samples stored at 4 °C or 80 °C with rapid (liquid
N2) freezing ﬁrst. Signiﬁcant loss of both occurs when stored at
4 °C or placed at 80 °C without ﬁrst being ﬂash frozen. Also, ﬂash
freezing did not alter the disposition between Hb and CFH (not
shown). In summary, these data show that plasma samples need
to be rapidly frozen to maintain Hb and CFH integrity and levels.
In summary, Figs. 1–4 show that widely used assays for CFH and
Hb are not speciﬁc for each species, and that depending on plasma
intrinsic factors, how MWt based separation was performed, how
samples are collected and stored, the levels of CFH may be under-
or overestimated.
3.4. Measurement of Hb and CFH in biological matrices
We developed and tested a spectral deconvolution approach to
simultaneously quantify Hb and CFH in plasma. This method relies
on the fact that CFH has a distinct absorbance spectrum compared
to oxidation and ligated forms of Hb present in vivo. Since any
absorbance spectrum containing a mixture of different species
reﬂects the concentration of each species multiplied by theFig. 4. OxyHb (5 mM) was added to plasma (Panel A) or PBS (Panel B) and spectra meas
400 mM) was then added to convert oxyHb to metHb, and then potassium cyanide (ﬁnal
at 540 nm between metHb and cyanometHb was 4.3 mM1  cm1 70.06 (mean7SEM
ferricyanide and potassium cyanide. Plasma was collected from healthy volunteers and s
CFH was added to plasma and then measured immediately and then stored at room tem
for 8d. Total heme was measured by QuantiChrom™ Heme assay kit. Hb was measuredextinction coefﬁcient at any given wavelength, spectra can be
analyzed by spectral deconvolution with least squares regression
ﬁtting, using standard spectra (Fig. 5A) of each species, to de-
termine the concentrations of individual species. We previously
validated this approach with RBC stored in Adsol storage media [6]
and showed that oxyHb, metHb and CFH can be quantitated by
collecting spectra pre- and post-reaction with potassium cyanide
to convert metHb to cyanometHb. Similar results were observed
with PBS (not shown).
We next tested the deconvolution method on plasma. A sig-
niﬁcant challenge is interference from other absorbing compo-
nents and scatter due to turbidity. As indicated above, bilirubin
absorbs light over the visible spectrum (Fig. 5A). We therefore
introduced both unconjugated and conjugated bilirubin into
spectral deconvolution algorithms. Plasma was collected from
healthy donors and spiked with different combinations of oxyHb,
metHb and CFH and spectra collected (450–700 nm, 1 cm path-
length). Fig. 5B shows representative spectra from one plasma
preparation. Fig. 5C shows residuals for deconvolution ﬁts, ex-
cluding bilirubin in the algorithm, and Fig. 5D plots the percent
recovery of oxyHb, metHb and CFH relative to the spiked con-
centration. Under these deconvolution conditions, oxyHb was
under estimated by 40% and whereas the average recovery of
metHb and CFH was relatively higher, the error associated with
these measurements was substantial. Including bilirubin in the
deconvolution improved ﬁts by 11.171.0 fold (mean7SEM,
n¼28) (Fig. 5E), however the residuals (Fig. 5F) remained high
and ﬁts poor. This is underscored by lower % recoveries for
added oxyHb, overestimation of metHb, and CFH being
undetectable (Fig. 5G). Thus, including bilirubin in spectral de-
convolution improves accuracy of ﬁts, but does not improve the
ability to discern between oxyHb, metHb or CFH. To minimize the
contribution of bilirubin, we next tested if limiting the wave-
length scan range to between 520 nm and 700 nm would im-
prove ﬁts and ability to distinguish Hb and CFH. Fig. 5H–I showured. Respective blank spectra were PBS in each case. Potassium ferricyanide (ﬁnal
500 mM) added to form cyanometHb (pH 7.4). Calculated delta extinction coefﬁcient
, n¼3). Panel C shows spectra of hemin in the presence or absence of potassium
piked with indicated concentrations of oxyHb (Panel D) or CFH (Panel E). OxyHb or
perature, 4 °C, 80 °C, or ﬁrst rapidly frozen in liquid N2 and then stored at 80 °C
as outlined in Panel A.
Fig. 5. Panel A: Standard spectra of oxyHb, metHb, cyanometHb, hemin, conjugated and unconjugated bilirubin prepared in PBS, pH 7.4. Plasma was prepared from 3 healthy
donors and spiked with indicated concentrations of oxyHb, metHb and CFH. Spectra were measured between 450 and 700 nm in 1 cm or 1 mm cuvettes as indicated. Also
where shown, spectra were measured after addition of potassium cyanide (400 mM, 10 min, 22 °C). Conditions: Panels B–D: 1 cm cuvette, deconvolution using oxyHb, metHb
and CFH between 450 and 700 nm; Panels E–G: 1 cm cuvette, deconvolution using oxyHb, metHb, CFH, conjugated bilirubin and unconjugated bilirubin between 450 and
700 nm; Panels H–K: 1 cm cuvette, deconvolution using oxyHb, metHb, CFH, conjugated bilirubin, unconjugated bilirubin or with cyanometHb between 520 and 700 nm;
Panels l–O: 1 mm cuvette, deconvolution using oxyHb, metHb, CFH, conjugated bilirubin, unconjugated bilirubin, or with cyanometHb between 520 and 700 nm. Panels B,
E, H and L show representative spectra from a single donor with dotted lines indicated ﬁts after deconvolution. Panels C, F, I and M show residuals for deconvolution ﬁts for
respective spectra. Panels D, G, J, K, N and O show percent recovery of added oxyHb, metHb, CFH and cyanometHb from respective deconvolution analyses across all groups.
Data in bar graphs are mean7SEM (n¼3).
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these conditions, 8370.8% of added oxyHb and 8673.2% of
added CFH was measurable (mean7SEM, n¼4); however metHb
was underestimated by ∼50% (Fig. 5J). To improve metHb de-
tection, we added potassium cyanide to form cyanometHb and
then performed deconvolution analysis again. In this case
(Fig. 5K) both oxyHb and CFH recovery decreased slightly
(7871.2% and 6874% respectively), but metHb was now de-
tectable with a recovery of ∼110%. Finally, to limit scatter asso-
ciated with turbidity, we measured spectra from the same sam-
ple in a 1 mm pathlength cuvette; while this will decrease sen-
sitivity per the Beer-Lambert law, scatter effects will also di-
minished. Fig. 5L–N shows that this protocol resulted in the most
optimal oxyHb and CFH recovery (9271.3% and 10376.1% re-
spectively), but again cyanide was required to detect metHb
(Fig. 5O). In summary, these data suggest that deconvolution of
visible spectra of plasma7potassium cyanide, collected between
520 and 700 nm in both 1 cm and 1 mm cuvettes is able toreliably and simultaneously quantitate oxyHb, metHb (via
CNmetHb) and CFH with 490% accuracy.
3.4.1. Application of deconvolution method to SCD plasma
61 plasma samples were collected from 19 pediatric SCD pa-
tients and 7 plasmas from age- and sex-matched control patients
(see Table 1). Visible spectra were measured from 450–700 nm in
1 mm cuvettes and deconvolution analyses performed between
520 and 700 nm. Fig. 6A shows representative spectra of SCD
plasma that contained varying ratios of oxyHb: CFH. Fig. 6B plots
the oxyHb, metHb and CFH levels, and Fig. 6C the relative con-
centrations of oxyHb, metHb (CNmetHb) and CFH within each
sample. Fig. 6D plots the relationship between oxyHb and CFH in
VOC and ACS samples. Interestingly, while there was no signiﬁcant
correlation in ACS samples, with VOC, a positive correlation be-
tween oxyHb and CFH was observed. Finally, to further validate
the deconvolution results, Hb levels were also measured by ELISA.
Fig. 6E shows a correlation of 0.94 between the two approaches.
Table 1
Demographic data of the control and sickle cell patients included in this study. A
total of 61 plasma samples were collected from 19 pediatric SCD patients. Samples
for 2 out of the 19 patients were collected on separate admissions. Two patients
were excluded due to improper handling of their samples (a total of 4 plasma
samples), 3 samples excluded from analysis as they were collected during wellness
visits and 1 sample excluded as it was collected from a patient who underwent red
cell apheresis within the previous 24 h prior to collection. Of the 17 included pa-
tients, 12 were admitted with vasoocclusive crisis (VOC) and 6 with acute chest
syndrome (ACS). Control patients were obtained from a population of otherwise
healthy, age and race-matched patients undergoing procedures in the OR. These
procedures included 2 patients undergoing a cardiac catheterization, one inguinal
hernia repair, one esophageal foreign body removal, one keloid injection, one cir-
cumcision, and one umbilical hernia repair. One control sample was excluded from
analysis secondary to the presence of chronic health conditions including a past
heart transplant which was not known at the time of collection.
Control Sickle cell patient
All VOC ACS
N 7 17 12 5
Mean age
(yrs)
8.4
(4–17)
12.3
(4–19)
13.6
(5–19)
9
(4–18)
Gender Male 5 8 6 2
Female 2 9 6 3
Race African American 7 16 11 5
Hispanic 0 1 1 0
Hb SS 0 17 12 5
Sβ0-thalassemia 0 0 9 0
Chronic
therapy
Hydroxyurea 0 15 11 4
Monthly
transfusion
0 1 1 0
Fig. 6. Plasma was collected from control or SCD patients and spectra measured pre- an
between 520 and 700 nm using base spectra of oxyHb, metHb, CNmetHb (when CN w
presentative spectra of SCD plasma samples in which varying ratios of Hb:CFH were det
oxyHb, metHb (derived from CN-metHb after potassium cyanide addition) and CFH mea
metHb and CFH in control, or SCD patients with VOC or ACS. Panel D: Relationship be
determined by linear regression with 95% conﬁdence interval bands for VOC group only
(n¼13). Panel E: Hemoglobin levels were determined by ELISA and deconvolution. Lin
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microvesicles
Recent studies have suggested that red-cell derived micro-
vesicles contain CFH and mediate endothelial dysfunction in SCD
[29,37]. To test the deconvolution method and evaluate if micro-
vesicles formed during RBC storage similarly contain CFH, micro-
particles (MP) and exosomes (Exo) were prepared from stored
RBCs. MPs were more abundant (284759 109 vs. 89720109
particles/mL) and larger (13674.6 nm and 11379.1 nm) com-
pared to Exo (all data mean7SEM, n¼7). Fig. 7A shows re-
presentative spectra of MP and Exo together with ﬁts from de-
convolution analyses; residuals are shown in Fig. 7B–C. Fits were
relatively poor due to turbidity, but improved between 3 and 16
fold by addition of 0.01–0.05% triton (Fig. 7A–C). Fig. 7D plots the
concentration of Hb and CFH normalized per mL of starting ma-
terial and Fig. 7E per particle. CFH was lower compared to Hb per
MP or Exo, with greater number of particles leading to higher Hb
amounts between MP and Exo (Fig. 7D).4. Discussion
The emerging importance of Hb and CFH in acute diseases
characterized by oxidative stress and associated with low to high
levels of hemolysis is underscored by both biomarker and pre-
dictive considerations, where these species are associated with
adverse outcomes, and pre-clinical data showing causative roles in
mediating vascular and end-organ inﬂammation and toxicity.
These considerations necessitate methods that can measure each
selectively and with sufﬁcient sensitivity in biological matrices.d post- potassium cyanide treatment in 1 mm cuvettes. Spectra were deconvoluted
as added), hemin, conjugated bilirubin and unconjugated bilirubin. Panel A: re-
ermined. Dotted lines represent ﬁts from deconvolution. Panel B: Concentration of
sured in control or SCD patients with VOC or ACS. Panel C: Distribution of oxyHb,
tween oxyHb and CFH in SCD-VOC and SCD-ACS patients. Shown are best-ﬁt lines
(n¼40). No signiﬁcant relationship between oxyHb and CFH in ACS was observed
e shows best ﬁt by linear regression with 95% conﬁdent interval.
Fig. 7. Microparticles and exosomes were prepared from leukoreduced RBC (in Adsol) collected from bags stored for 30–52d. Panel A: Representative absorbance spectra of
MP and exosome fractions in the absence or presence of 0.01–0.05% triton. Dotted lines show best ﬁts by spectral deconvolution using base spectra of oxyHb, metHb, and
hemin. Panel B–C show residuals before (black lines) and after triton (red lines) for microparticles and exosomes respectively. Panel D plots concentrations of oxyHb and
CFH in microparticle (MP) and exosome fractions (Exo). Panel E plots these species per particle. *po0.05 by paired t-test. Data are mean7SEM (n¼7). (For interpretation of
the references to color in this ﬁgure legend, the reader is referred to the web version of this article).
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CFH together (i.e. total heme), Hb or CFH alone. As shown herein,
most currently used methods are not selective, as they rely on
properties that are similar for both CFH and Hb. We have not
tested all previously used approaches but note that redox cycling
and/or absorbance changes at a single wavelength are commonly
used, and other approaches e.g. heme-pyridine extraction, rely on
removing CFH from Hb ﬁrst, again precluding distinguishing be-
tween these species. Since these methods will measure both CFH
and Hb at least additively, one or the other will be overestimated.
This potential error is compounded if sample collection and pro-
cessing leads to change in disposition between different heme-
species (for example metHb is more sensitive to degradation by
freeze-thawing and heme sequestered in hydrophobic compart-
ments (e.g. lipids) will be lost if these are pelleted), and by the fact
that variables that affect CFH and Hb redox cycling are often
overlooked. Moreover, single wavelength monitoring does not
account for other species that may absorb at that wavelength.
We applied a spectral deconvolution method to measure Hb
and CFH in plasma. Using a stepwise process that improved
spectral ﬁts by least squares ﬁtting, we show that inclusion of
bilirubin spectra, limiting the wavelength range over which de-
convolution is performed and using a 1 mm cuvette, allowed
measurement of Hb and CFH with 490% accuracy, and in plasmas
from different donors that displayed distinct degrees of turbidity.
Addition of cyanide, to form cyanometHb then allows for metHb
measurement. There are limitations to this approach however. It is
possible that we have not accounted for all absorbing species in
plasma. Absorbance based approaches may be limited in terms of
sensitivity, however spiking with 2 mM of heme-species was
readily detectable. Another consideration is if one heme-species is
present at much higher concentrations than the other, sensitivity
of deconvolution to discern low levels will be challenging. Indeed,
the largest discrepancy between deconvolution results with ELISA
based measures of oxyHb was in plasma that had the highest le-
vels of oxyHb (4100 mM, not shown). This limitation isaddressable by sample dilution however. Finally, absorbance will
measure both free and bound (to haptoglobin and hemopexin)
forms of Hb and CFH. This can be viewed as both an advantage and
possible limitation as it allows measurement of the total, but the
free forms are likely more important for mediating toxicity. Irre-
spective of the method employed, it is important to measure these
acute phase proteins at the same time as Hb and CFH, to fully
evaluate the role of the latter in a given pathophysiological setting.
We also note that there are other methods selective for Hb or CFH.
Immuno-based (antibody capture ELISA or Western blotting) are
selective for Hb but will not measure CFH. CFH can be selectively
measured by addition of ApoMb and following Mb formation [38]
and a recent study reports on ﬂuorescent heme-sensors for cell-
based measurements [39]. However, the amenability of such ap-
proaches to plasma remains unclear.
We also applied deconvolution to quantify Hb and CFH in MP
and Exo isolated from stored RBCs. The concept that hemoglobin
and heme may be carried in red cell derived vesicles is relatively
new [8,29]. No studies to our knowledge have applied vigorous
protocols to measure the exact and relative amounts of he-
moglobin and heme in these, however. The main limitation of
sample turbidity and light scattering was overcome by addition of
mild detergent. Using this approach we showed that per particle,
Hb and CFH does not differ between MP or Exo, with Hb being 10–
15 fold greater than CFH. Notably, while a normal distribution of
CFH was observed in Exo, with MP two populations could be
discerned with CFH being detectable or not. Further studies are
required to test if these are indeed distinct particles.
A clear advantage of the deconvolution approach is its simpli-
city, most labs have access to UV–visible spectrophotometers and
the fact that oxyHb, metHb and CFH can be determined simulta-
neously with little sample handling and reactions involved. We
suggest that spectra be measured preferably on freshly obtained
samples, or samples undergone a single freeze-thaw cycle, pre-
and post-cyanide reaction using both 1 cm and 1 mm cuvettes.
Using this approach we measured plasma Hb and CFH in pediatric
J.-Y. Oh et al. / Redox Biology 9 (2016) 167–177176SCD patients diagnosed with VOC and ACS. The mean and range of
concentrations of oxyHb were similar to that observed in adult
SCD [9]. Our measures of CFH levels however, were higher than
previous reports [27]. We speculate this difference is due to un-
derestimation of CFH in prior studies due to use of Centricons to
separate plasma CFH and Hb, which we show (Fig. 3) removes CFH
from plasma or PBS. Notably, CFH levels were similar in magnitude
to oxyHb. Thus, quantitatively oxyHb may not be the predominant
free heme-containing species in hemolytic syndromes. We also
note that there was signiﬁcant variance in Hb and CFH levels
amongst VOC and ACS groups. Despite this a positive correlation
between HB and CFH was observed in VOC, but not ACS. We have
no mechanistic insights into this potential difference between VOC
and ACS, and note that sample size limitations preclude forward-
ing generalizable conclusions and we present these data to un-
derscore the need for more extensive assessment of Hb vs. CFH
levels in other disease states using accurate methods, which will in
turn better complement studies evaluating the causative roles of
these species in disease pathogenesis.Author contributions
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